The European regulator proved that the Janssen drug causes an atypical type of thrombosis, but recognized the Janssen vaccine itself as safe
This is stated in the official statement of the EU pharmaceutical regulator on April 20.
“The EMA’s scientific assessment confirms the safe and effective use of COVID-19 vaccines. The use of the vaccine during national vaccination campaigns will take into account the pandemic situation and the availability of the vaccine in the individual Member States, “ the document reads.
But at the same time, the EMA confirmed the link between the Janssen vaccine and the occurrence of thrombosis in people who received the vaccine.
However, the EMA safety committee recommended adding “very rare cases of unusual blood clots with low platelet counts” to the list of vaccine side effects.
At the same time, the ratio of the benefits of this drug to the possible risks in the EMA was assessed as positive.
“The EMA has found a link between the vaccine and very rare cases of thrombosis. The EMA confirms that the overall risk/benefit ratio remains positive… A warning about the risk of developing thrombosis should be added to the product information, “ the report says.
Earlier, the media reported that the European Commission in 2022 will not extend the contracts for the supply of vaccines to AstraZeneca and Johnson & Johnson.